“Shift from Plasma-Derived to Recombinant C1-INH Products”
Recombinant C1-INH therapies are gaining traction due to their potential for higher purity and consistency compared to plasma-derived alternatives. Recombinant therapies also carry a lower risk of bloodborne pathogen transmission, which is a significant concern for plasma-based products. This shift is influencing the market as patients and healthcare providers opt for the safety and reliability of recombinant therapies. Leading companies are focusing on the development and commercialization of recombinant C1-INH products, which are seen as the future of treatment for hereditary angioedema and other complement-related disorders.
Frequently Asked Questions
The market is segmented based on Global Plasma Protease C1-inhibitor Market Segmentation, By Drug Class (C1-inhibitors, Kallikrein Inhibitor, and Selective Bradykinin B2 Receptor Antagonist), Dosage Form (Lyophilised and Injectables), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) – Industry Trends and Forecast to 2032
.
The Global Plasma Protease C1 Inhibitor Market size was valued at USD 909.85 USD Million in 2024.
The Global Plasma Protease C1 Inhibitor Market is projected to grow at a CAGR of 7.6% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Italy, Spain, Netherlands, Russia, Denmark, Norway, Rest of Europe in Europe, China, Japan, India, Malaysia, South Korea, Australia, Malaysia, Thailand, Vietnam, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Kuwait, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
